Use fundamental data analysis to confirm all available indicators of Therapix Biosciences to find out if markets are presently mispricing the corporation. We found sixteen available drivers for Therapix Biosciences Ltd which can be compared to its competition. Use Therapix Biosciences Net Income, Book Value Per Share, Beta, as well as the relationship between Cash per Share and Earnings Per Share to make sure your decision on pricing Therapix Biosciences is adequate. Use Therapix Biosciences to enhance returns of your portfolios. The stock experiences unexpected upward trend. Watch out for market signals. Check odds of Therapix Biosciences to be traded at 40.44 in 30 days.
Therapix Biosciences Company Summary
Therapix Biosciences competes with Ormat Technologies. Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. Therapix Biosciences operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange. It employs 9 people.
Therapix Biosciences Market Capitalization vs Book Value Per Share
Therapix Biosciences Ltd is rated second in market capitalization category among related companies. It is rated second in book value per share category among related companies . The ratio of Market Capitalization to Book Value Per Share for Therapix Biosciences Ltd is about 1,492,000,000
Therapix Biosciences Market Fundamentals
Therapix Biosciences April 22, 2019 Opportunity Range